A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.
<h4>Background</h4>Pyrazinamide (PZA) is crucial for tuberculosis (TB) treatment, given its unique ability to eradicate persister bacilli. The worldwide burden of PZA resistance remains poorly described.<h4>Methods</h4>Systematic PubMed, Science Direct and Scopus searches for...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0133869 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849320735938445312 |
|---|---|
| author | Michael G Whitfield Heidi M Soeters Robin M Warren Talita York Samantha L Sampson Elizabeth M Streicher Paul D van Helden Annelies van Rie |
| author_facet | Michael G Whitfield Heidi M Soeters Robin M Warren Talita York Samantha L Sampson Elizabeth M Streicher Paul D van Helden Annelies van Rie |
| author_sort | Michael G Whitfield |
| collection | DOAJ |
| description | <h4>Background</h4>Pyrazinamide (PZA) is crucial for tuberculosis (TB) treatment, given its unique ability to eradicate persister bacilli. The worldwide burden of PZA resistance remains poorly described.<h4>Methods</h4>Systematic PubMed, Science Direct and Scopus searches for articles reporting phenotypic (liquid culture drug susceptibility testing or pyrazinamidase activity assays) and/or genotypic (polymerase chain reaction or DNA sequencing) PZA resistance. Global and regional summary estimates were obtained from random-effects meta-analysis, stratified by presence or risk of multidrug resistant TB (MDR-TB). Regional summary estimates were combined with regional WHO TB incidence estimates to determine the annual burden of PZA resistance. Information on single nucleotide polymorphisms (SNPs) in the pncA gene was aggregated to obtain a global summary.<h4>Results</h4>Pooled PZA resistance prevalence estimate was 16.2% (95% CI 11.2-21.2) among all TB cases, 41.3% (29.0-53.7) among patients at high MDR-TB risk, and 60.5% (52.3-68.6) among MDR-TB cases. The estimated global burden is 1.4 million new PZA resistant TB cases annually, about 270,000 in MDR-TB patients. Among 1,815 phenotypically resistant isolates, 608 unique SNPs occurred at 397 distinct positions throughout the pncA gene.<h4>Interpretation</h4>PZA resistance is ubiquitous, with an estimated one in six incident TB cases and more than half of all MDR-TB cases resistant to PZA globally. The diversity of SNPs across the pncA gene complicates the development of rapid molecular diagnostics. These findings caution against relying on PZA in current and future TB drug regimens, especially in MDR-TB patients. |
| format | Article |
| id | doaj-art-555a7cf2464d4b76baa09c577035ef0c |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-555a7cf2464d4b76baa09c577035ef0c2025-08-20T03:49:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013386910.1371/journal.pone.0133869A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.Michael G WhitfieldHeidi M SoetersRobin M WarrenTalita YorkSamantha L SampsonElizabeth M StreicherPaul D van HeldenAnnelies van Rie<h4>Background</h4>Pyrazinamide (PZA) is crucial for tuberculosis (TB) treatment, given its unique ability to eradicate persister bacilli. The worldwide burden of PZA resistance remains poorly described.<h4>Methods</h4>Systematic PubMed, Science Direct and Scopus searches for articles reporting phenotypic (liquid culture drug susceptibility testing or pyrazinamidase activity assays) and/or genotypic (polymerase chain reaction or DNA sequencing) PZA resistance. Global and regional summary estimates were obtained from random-effects meta-analysis, stratified by presence or risk of multidrug resistant TB (MDR-TB). Regional summary estimates were combined with regional WHO TB incidence estimates to determine the annual burden of PZA resistance. Information on single nucleotide polymorphisms (SNPs) in the pncA gene was aggregated to obtain a global summary.<h4>Results</h4>Pooled PZA resistance prevalence estimate was 16.2% (95% CI 11.2-21.2) among all TB cases, 41.3% (29.0-53.7) among patients at high MDR-TB risk, and 60.5% (52.3-68.6) among MDR-TB cases. The estimated global burden is 1.4 million new PZA resistant TB cases annually, about 270,000 in MDR-TB patients. Among 1,815 phenotypically resistant isolates, 608 unique SNPs occurred at 397 distinct positions throughout the pncA gene.<h4>Interpretation</h4>PZA resistance is ubiquitous, with an estimated one in six incident TB cases and more than half of all MDR-TB cases resistant to PZA globally. The diversity of SNPs across the pncA gene complicates the development of rapid molecular diagnostics. These findings caution against relying on PZA in current and future TB drug regimens, especially in MDR-TB patients.https://doi.org/10.1371/journal.pone.0133869 |
| spellingShingle | Michael G Whitfield Heidi M Soeters Robin M Warren Talita York Samantha L Sampson Elizabeth M Streicher Paul D van Helden Annelies van Rie A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. PLoS ONE |
| title | A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. |
| title_full | A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. |
| title_fullStr | A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. |
| title_full_unstemmed | A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. |
| title_short | A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. |
| title_sort | global perspective on pyrazinamide resistance systematic review and meta analysis |
| url | https://doi.org/10.1371/journal.pone.0133869 |
| work_keys_str_mv | AT michaelgwhitfield aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT heidimsoeters aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT robinmwarren aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT talitayork aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT samanthalsampson aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT elizabethmstreicher aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT pauldvanhelden aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT anneliesvanrie aglobalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT michaelgwhitfield globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT heidimsoeters globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT robinmwarren globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT talitayork globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT samanthalsampson globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT elizabethmstreicher globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT pauldvanhelden globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis AT anneliesvanrie globalperspectiveonpyrazinamideresistancesystematicreviewandmetaanalysis |